

Introducing The NEW Research Accelerator for Follicular Lymphoma (RAFL) Program, which is now Accepting Letters of Intent Through September 9, 2024, at 3 pm EST



The Research Accelerator for Follicular Lymphoma (RAFL) is a strategic partnership between the Institute for Follicular Lymphoma Innovation (IFLI) and The Leukemia & Lymphoma Society (LLS), committing at least \$20 million over seven years to foster innovative research in Follicular Lymphoma (FL). RAFL aims to tackle challenging issues in FL by funding ambitious research proposals globally, with two funding cycles planned: RAFL-I (opening 2024) and RAFL-II (opening 2026). Research will focus on understanding FL's biology, developing new therapies, and launching clinical programs to meet unmet patient needs, with the ultimate goal of curing FL.

The program encourages cross-disciplinary collaboration and industry partnerships, seeking established investigators with significant contributions to FL or related fields. Special expertise in areas like epigenetics, data science/AI, and neoantigen discovery is welcomed. Funding includes Synergistic Team Awards (STA) for coordinated efforts to understand disease mechanisms and develop novel therapies, with \$6.5 million over five years, and Translational Awards (TRL) to move therapeutic candidates towards clinical trials, offering up to \$1.75 million over five years. STA requires a program director leading 2-4 synergistic projects, while TRL focuses on translational research with substantial preliminary data.

A detailed description of the Research Accelerator for Follicular Lymphoma program and application instructions are available on the [RAFL Program Overview](#) or [LLS Research Portal](#).

For additional questions regarding LLS research grant programs, eligibility, and application processes, please contact researchprograms@lls.org.